Cantor Fitzgerald Forecasts CTMX FY2025 Earnings

Key Points

• Cantor Fitzgerald has projected CytomX Therapeutics will report earnings of ($0.01) per share for FY2025, improving from the consensus estimate of ($0.05) per share.
• The stock has a current market cap of $339.71 million with strong interest from institutional investors, of which approximately 67.77% is held by hedge funds.
• Research firms such as Barclays and Oppenheimer have recently initiated coverage with price targets of $3.50 and $7.00, respectively, reflecting positive sentiment in the market.

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of CytomX Therapeutics in a research report issued to clients and investors on Monday, September 22nd. Cantor Fitzgerald analyst O. Brayer forecasts that the biotechnology company will post earnings of ($0.01) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for CytomX Therapeutics' current full-year earnings is ($0.05) per share. Cantor Fitzgerald also issued estimates for CytomX Therapeutics' FY2026 earnings at ($0.29) EPS.

A number of other research firms have also recently commented on CTMX. Barclays assumed coverage on CytomX Therapeutics in a research report on Wednesday, September 17th. They set an "overweight" rating and a $3.50 price objective for the company. Oppenheimer assumed coverage on shares of CytomX Therapeutics in a research note on Thursday, July 31st. They issued an "outperform" rating and a $7.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $5.42.

CytomX Therapeutics Price Performance

CTMX stock opened at $2.06 on Tuesday. The company has a market cap of $339.71 million, a P/E ratio of 3.68 and a beta of 2.18. CytomX Therapeutics has a 1 year low of $0.40 and a 1 year high of $3.10. The stock's fifty day moving average price is $2.15 and its 200-day moving average price is $1.73.

Hedge Funds Weigh In On CytomX Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its stake in CytomX Therapeutics by 188.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 29,661 shares of the biotechnology company's stock worth $67,000 after purchasing an additional 19,384 shares in the last quarter. Soleus Capital Management L.P. purchased a new position in shares of CytomX Therapeutics during the second quarter valued at about $2,961,000. Perceptive Advisors LLC bought a new stake in shares of CytomX Therapeutics in the second quarter worth about $15,876,000. Lazard Asset Management LLC lifted its position in shares of CytomX Therapeutics by 5,208.3% in the second quarter. Lazard Asset Management LLC now owns 43,316 shares of the biotechnology company's stock worth $98,000 after buying an additional 42,500 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in CytomX Therapeutics during the second quarter valued at approximately $6,505,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.